Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report
Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 323 KB, PDF-dokument
Originalsprog | Engelsk |
---|---|
Tidsskrift | HemaSphere |
Vol/bind | 6 |
Udgave nummer | 11 |
Sider (fra-til) | E789 |
ISSN | 2572-9241 |
DOI | |
Status | Udgivet - 2022 |
Bibliografisk note
Funding Information:
EPICOVIDEHA has received funds from Optics COMMITTM (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223). The funder of the study had no role in study design, data analysis, interpretation, or writing of the report. All authors had full access to the data and had final responsibility for the decision to submit for publication.
ID: 341015599